Trial reportNature2025
Phase I/II trial of iPS-cell-derived dopaminergic cells for Parkinson's disease.
Trial report in Nature, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 107 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
107 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Homogenous Cell Transplantation Trials in Parkinson's Disease: A Systematic Review and Meta-Analysis.Movement disorders clinical practice · 2026Pooled it
- A Systematic Review on Disease-Modifying Therapies in Parkinsonian Disorders.Clinical pharmacology and therapeutics · 2026Pooled it
- Pooled it
- Human embryonic stem cell-derived dopaminergic cells for Parkinson's disease: a phase 1/2 open-label trial.Nature medicine · 2026Trial
- Silencing of optogenetic and chemogenetic transgenes in human iPSCs involves promoter methylation and methylation-independent mechanisms.Epigenetics · 2026Article
- Genetically engineered hypoimmunogenic iPSCs: Strategies and considerations for clinical applications.Regenerative therapy · 2026Review
- Advancements in differentiation of induced pluripotent stem cells into specialized neuronal subtypes.Neural regeneration research · 2026Article
- Combinatorial mechanisms specify cellular location and neurotransmitter identity during planarian neurogenesis.Nature communications · 2026Article
- Review
- Review
- Neuroinflammation and Graft Survival in Pluripotent Stem Cell-Derived Therapies for the Central Nervous System.Journal of neurochemistry · 2026Review
- Human iPSC‑based translational and reverse translational research for neurodegenerative diseases: emphasis on ALS and key advances.Japanese journal of radiology · 2026Review
- Induced pluripotent stem cells from discovery to translation.Nature medicine · 2026Review
- An iPSC-derived neural progenitor cell therapy for subacute spinal cord injury: a phase 1 trial with long-term follow-up.Nature medicine · 2026Article
- Ginsenosides: potential therapeutic implications in neurodegenerative diseases by inhibiting ferroptosis.Molecular biology reports · 2026Review
- Pluripotency, differentiation, and reprogramming: 20 years of induced pluripotent stem cells.BMC biology · 2026Article
- Global research synergy: Advancing fundamental Parkinson's research through international collaboration.Journal of Parkinson's disease · 2026Review
- Implantation of autologous peripheral nerve tissue to the nucleus basalis of Meynert in patients with Parkinson's disease during deep brain stimulation surgery: a 2-year report of safety, feasibility, and clinical response.Journal of neurosurgery · 2026Article
- Advancing disease-modifying therapies for Parkinson's disease: Current strategies and future directions.Innovation (Cambridge (Mass.)) · 2026Review
- A revolutionary stem-cell therapy must proceed responsibly to achieve its full potential.Nature · 2026Article
47 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease is caused by the loss of dopamine neurons, causing motor symptoms. Initial cell therapies using fetal tissues showed promise but had complications and ethical concerns
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.